Science & Innovation Theaters

Science & Innovation Theaters provide a structured focus for participants to learn about specific products, therapeutic areas, and/or disease states in presentations given by company designated presenters. 

All Theaters take place in The Expo on Thursday and Friday. 

Materials presented in theaters may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit. 

Thursday, March 31 | 11:15am–11:45am 

Theater #1
CGM Access: Exploring the Clinical and Economic Impacts of Continuous Glucose Monitoring in Diabetes Care   

Description: Join Abbott, a global leader in diabetes care, for a discussion on the benefits of continuous glucose monitoring for patients with diabetes. Review real world data and explore how continuous glucose monitoring systems can enable health care providers to optimize medication therapy and improve diabetes outcomes. Gain insights into how these tools may be utilized across all patient types to meet the ADA’s recommendations for Standards of Care. 


  • Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, Clinical Pharmacist and Professor, Midwestern University College of Pharmacy and Advocate Medical Group 

Sponsored by Abbott Diabetes Care 

Theater #2 
Enhancing the Pharmacy Care Management Model: Analytics and Clinical Pharmacy Services for Medically Complex Plan Members 

Description: Join Tori Erxleben-Rush, PharmD, of RxAnte, and Sapna Patel, RPh, of Mosaic Pharmacy Service to learn how an analytics-backed pharmacy care management program is optimizing MAPD plan outcomes while transforming the pharmacy experience for medically complex plan members. Attendees will learn how population health analytics and an enhanced pharmacy care management model can meet an industrywide need to reduce medical utilization, improve measures of pharmacy quality, and enhance members’ pharmacy experience.  

Topics will include: 

  • The industry-wide trend of increasing medical complexity of MAPD plan membership  
  • The process of identifying high-need plan members for enrollment into clinically intensive pharmacy care management programs. 
  • The distinct needs of medically complex plan members.  
  • How a pharmacy care management program works to improve outcomes for MAPD plans and their members. 
  • A case study highlighting the impact of the pharmacy model, including improved cost of care, improved adherence, and lower of out-of-pocket costs. 


  • Tori Erxleben-Rush, PharmD, Director, Clinical Pharmacy Programs, RxAnte 
  • Sapna Patel, RPh, Director, Clinical Services, Mosaic Pharmacy Service 

Sponsored by RxAnte 

Thursday, March 31 | Noon–12:30pm 

Theater #1  
Advancing the Science of Medication Safety 

Description: MedWise HealthCare, a division of Tabula Rasa HealthCare, is a leading provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to improve outcomes and quality measures. Our MedWise® Science technology analyzes and compares how medications interact in aggregate, identifying patients at risk for adverse drug events. MedWise Science provides clinical tools and actionable insights to prevent hospitalizations and emergency room visits, reducing the total cost of care. Our MedWise-certified pharmacists and network of more than 18,000 community pharmacies personalize medication regimens to improve efficacy, adherence, and reduce polypharmacy. Through a suite of solutions, we offer vast opportunities for enhancing patient care and satisfaction for payers, providers, and other organizations. 


  • Brian Peltz, MS, RPh, FACHE, Area Vice President, Tabula Rasa HealthCare 
  • Alexis Garcia, PharmD, Regional Director, Business Development, Tabula Rasa HealthCare 

Sponsored by MedWise HealthCare, a TRHC Division   

Theater #2 
Incorporating Dexcom G6 in a Pharmacist-Led Disease Management Program: Can You Afford Not To?

Description: Continuous glucose monitoring (CGM) provides a visual context to an individual’s current time-in-range and helps both the person and the healthcare professional identify areas to improve. Join our program to understand the clinical benefits of the Dexcom G6 CGM System and learn the process of how one health system incorporated CGM into their disease management program. 

Diabetes is complex, and the current model of care, measuring an A1C every three months, does not adequately capture each individual’s glucose ranges thus making it challenging to make therapeutic treatment decisions. This presentation will review recent evidence on the use of continuous glucose monitoring. The speaker will share Dexcom G6 implementation steps, tips for integrating into your system, and program outcomes. 


  • Eric Long, PharmD, MBA, BS, Disease Management Pharmacist, Beacon Health System 

Sponsored by Dexcom 

Thursday, March 31 |12:45pm-1:15pm 

Theater #1  
Advances in the Treatment of ANCA-Associated Vasculitis 

Description: This presentation will provide an overview of treatment considerations for ANCA-associated vasculitis and an understanding of the phase 3 ADVOCATE trial.  Specific topics will include the ADVOCATE efficacy and safety data supporting the approval of TAVNEOS® (avacopan) for adult patients with severe active ANCA-associated vasculitis, as well as appropriate dosing and administration of TAVNEOS for eligible patients. 


  •  Alexa Simon Meara, MD, Assistant Professor of Rheumatology, The Ohio State Wexner Medical Center, Division of Rheumatology

Sponsored by ChemoCentryx, Inc. 

Theater #2 
Precision Medicine to Address the Unmet Needs in Oncology 


Science & Innovation Theater Objectives: 

  • Understand the current advances of personalized medicine in oncology  
  • Identify unmet needs for oncology patients in the current environment  
  • Discuss how targeted therapies may address these unmet needs  
  • Explore Seagen’s portfolio and pipeline of targeted oncology therapies 


  • Ryan J. Haumschild, PharmD, MS, MBA, Director of Pharmaceutical Services, Emory Healthcare and Winship Cancer Institute
  • Deepak Singh, Senior Director, Clinical Value & Outcomes, Seagen

Sponsored by Seagen 

Thursday, March 31 | 1:30-2pm

Theater #1
Omnipod® 5 Automated Insulin Delivery System-Advances in Automated Insulin Delivery 

Description: The Omnipod® 5 Automated Insulin Delivery System is the first wearable, on-body, tubeless, automated insulin delivery system. The Omnipod® 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App on an Insulet-provided Controller or installed on a compatible smartphone*. The Omnipod® 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to your personal needs. This presentation will provide an overview of how the Omnipod® 5 System works and a summary of both the pivotal trial clinical outcomes and extension data, including efficacy and safety data. This Omnipod® 5 System is exclusively available through the Pharmacy Channel. 
*For a list of compatible smartphone devices visit


  • Laura Robbins, MS, RD, CDCES, ADEPT™ Certified, Senior National Account Manager, Insulet Corporation 
  • Michelle Tori, RD, CDCES, ADEPT™ Certified, Senior National Account Manager - Medicaid, Insulet Corporation 

Sponsored by Insulet

Theater #2
Unmet Need in Hemophilia B & The Value of Gene Therapy  

Description: Hemophilia B is a rare, X-linked, genetic disorder. People with the condition are particularly vulnerable to bleeds in their muscles, internal organs, and joints, leading to pain, swelling, and joint damage. Current treatment includes lifelong prophylactic infusions of factor IX (FIX) to temporarily replace or supplement low levels of the blood-clotting factor. Prophylactic treatment is associated with a significant economic burden and despite treatment, clinical burdens still exist. For people with hemophilia B, gene therapy has the potential to sustain blood-clotting ability by addressing the cause of the condition: a faulty gene for FIX. 


  • Robert R. Rouse, Head of US Market Access, CSL Behring Biotherapies for Life™ 
  • Debbie Bensen-Kennedy, Vice President Medical Affairs, CSL Behring Biotherapies for Life™ 

Sponsored by CSL Behring 

Friday, April 1 | 9:45-10:15am

Theater #1
New Digital Approach to Pain Management: Examining the Clinical Evidence 

Description: Chronic musculoskeletal (MSK) pain can be a common pathway to long-term opioid use and dependency. Long-term chronic pain management can be enhanced by wearable devices that deliver high-frequency impulse therapy to provide non-invasive and non-addictive pain relief. This educational session will share results of a randomized controlled clinical study on the effectiveness of Enso® - a high frequency impulse therapy wearable - to alleviate chronic MSK pain and improve functionality. Combined with seamless electronic medical record (EMR) integration, we’ll discuss how digital MSK care teams can monitor in-person provider orders in real-time and offer less-addictive options. In this session, you’ll walk away with innovative approaches for more effective chronic pain management.


  • Louis Dickey, MD & Medical Director, Hinge Health 

Sponsored by Hinge Health

Science & Innovation Theaters with a PIE logo include preapproval information exchange information. In accordance with federal laws and regulations, attendance at these sessions is restricted to payors, formulary committees, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the PIE information page

Additional Science & Innovation Theater sponsorship opportunities may be available. Contact Laura Larson, assistant director, national meeting sales, at for more details.